Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Resources, news and special offers to support you and your professional development during this difficult time.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
Download your copy of the new events calendar and see all the online workshops, conferences, RAC exams and European online workshops RAPS has planned for 2021 at a glance.
Registration is now open for RAPS Euro Convergence 2021! Attend to join peers from EU and around the world to gain insights and exchange ideas on the regions most pressing issues.
An invaluable resource for any professional engaged in designing, composing, compiling, or commenting on regulatory documentation
From self-assessments to help you identify your strengths and areas to focus on to reference books and online courses that will help you fill in the gaps in your regulatory knowledge, RAPS has the resources to help you prepare for the RAC exam.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
Posted 23 September 2016 | By Michael Mezher
The US Food and Drug Administration (FDA) on Friday announced it had approved Amgen's Amjevita (adalimumab-atto), the first biosimilar version of AbbVie's best-selling biologic Humira (adalimumab).
In July, FDA's Arthritis Advisory Committee voted unanimously to support the approval. Despite the approval, FDA did not clear Amgen's biosimilar for all 10 of Humira's indications. According to FDA, both drugs share the following six indications:
However, FDA says that Amjevita is only indicated for juvenile idiopathic arthritis in patients four or older, while Humira is indicated to treat patients as young as two or older. And, unlike Humira, Amjevita is not approved to treat pediatric Crohn's disease, hidradenitis suppurativa or uveitis.
According to FDA, Amjevita is also required to display a boxed warning on its label over the increased risk of serious infections when taking the drug.
As with the three previous US biosimilar approvals, FDA says it has not approved Amjevita to be interchangeable with Humira.
The approval marks the fourth biosimilar approved under the Biologics Price Competition and Innovation Act's 351(k) pathway, which allows sponsors an abbreviated path to market by demonstrating their product is biosimilar to a reference product. In early August, AbbVie filed a lawsuit to stop the marketing of Amgen's biosimilar to Humira and it remains to be seen when Amjevita may hit the US market. Humira first one approval in 2002.
FDA
Tags: Humira, Amjevita, Biosimilar, adalimumab, adalimumab-atto
Regulatory Focus newsletters
All the biggest regulatory news and happenings.